

CORPORATE

Current price 123p

Sector Chemicals

Code (PLA.L)

Listing AIM

SHARE PERFORMANCE



Source: Thomson Reuters, Allenby Capital

SHARE DATA

Market cap (£) 44m

Shares in issue (m) 35.75

52 weeks High Low
133.5p 90p

Financial year end 31 March

Source: Company Data, Allenby Capital

KEY SHAREHOLDERS

Livingbridge 11.71%

Camelot Capital 9.53%

Octopus Inv 8.93%

Downing LLP 8.39%

Faisal Rahmatallah 7.57%

Richard Vessey 7.00%

Arun Nagwaney 6.35%

Source: Thomson Reuters

Ian Jermin

+44 (0)20 3328 5664

i.jermin@allenbycapital.com

www.allenbycapital.com

PLASTICS CAPITAL PLC (PLA.L)

Full year update confirms strong organic growth

Plastics Capital plc has updated the market on its progress for the year to 31 March 2016 with results expected to be broadly in line with market forecasts. Organic sales growth has been strong, exceeding expectations in the Industrial Division and, with the exception of Palagan, also in the Films Division. The impact of currency movements has resulted in exports becoming significantly more competitive but the overall translation effect has been neutral due to hedging policies that delay any impact on profits by around two years. Palagan is the only subsidiary that is performing below par as it continues to undergo restructuring and management changes to improve its competitiveness. Our forecasts for 2016/17 and 2017/18 have been modestly revised downwards to accommodate for the restructuring and continued investment in the businesses. However, revenue forecasts have been raised to reflect a change in accounting policy whereby CCM and Mito will now be consolidated as subsidiaries, even though the Group's shareholdings in both are below 50%.

- It is encouraging that organic sales growth has exceeded expectations, particularly in the Bearings and Mandrel businesses which reported record years driven by new business wins that have now entered into production. Creasing Matrix continued to make progress expanding internationally through minority investments in sales and distribution businesses in the USA ("CCM") and in Italy ("Mito") and a relocation of the factory in China. Flexipol has traded well and Synpac is performing in line with expectations. Palagan continues to undergo restructuring designed to improve competitiveness. In the short term this has resulted in some weakness in trading which has temporarily had an impact on results but which we are equally confident will result in much improved trading in the medium term.
- Revenue forecasts raised, but profits revised downward. Strong trading has resulted in a £1m increase in revenue forecasts for FY17 although increased investment to underpin future growth, together with restructuring at Palagan, requires our adjusted profit forecast to be modestly reduced by 7% to 11.5p and FY2018 by around 4% to 12.4p.
- Change in accounting for investments – Following auditor's advice, CCM and Mito will now be treated as if they were subsidiaries and therefore fully consolidated in the P&L, with a deduction being made for non-controlling interests. This is in line with the Group's intention to fully acquire these businesses in due course. This should have no impact on EPS but raises revenues by around £5m for 2016/17.

EXHIBIT 1: SUMMARY OF FINANCIALS

Year End: March (£m)	2015A	2016A	2017E	2018E
REVENUE	39.6	50.8	65.6	75.8
EBITDA	5.3	5.9	6.9	7.8
PBT (NORMALISED)	3.7	4.1	4.3	4.9
EPS (p) NORMALISED	10.8	10.8	11.5	12.4
PE(x)	10.6	9.3	8.9	7.5
DIVIDEND (p)	4.00	4.40	4.62	4.85
YIELD	3.2%	3.6%	3.7%	3.9%

Source: Plastics Capital; Allenby Capital.

Allenby Capital acts as Joint Broker to Plastics Capital plc.

This document should be classified as marketing communication and all required disclosures appear on the last page of the report. This research is intended for UK institutional investors only. It is not intended for retail customers and any retail customers should seek professional, independent advice before investing. Additional information is available upon request.

FINANCIAL SUMMARY (UNDER NEW ACCOUNTING CONVENTION)

EXHIBIT 2: FINANCIAL SUMMARY				
	£m	£m	£m	£m
Y/E March	FY 2015A	FY 2016A	FY 2017E	FY 2018E
PROFIT & LOSS SUMMARY				
Revenue	39.576	50.803	65.600	75.750
Gross Profit	13.98	16.871	22.350	25.200
<i>margin</i>	35.3%	33.2%	34.1%	33.3%
Total Operating costs	-11.351	-14.707	-18.750	-21.050
<i>as a % of revenue</i>	28.7%	28.9%	28.6%	27.8%
Operating profit (before exceptional items)	2.399	2.457	3.600	4.150
EBITDA	5.257	5.886	6.900	7.800
<i>margin</i>	13.3%	11.6%	10.5%	10.3%
Non-controlling interests	0.000	0.000	-0.200	-0.200
Finance costs	-0.480	-0.722	-0.580	-0.750
Profit/(Loss) before tax (adjusted)	3.673	4.061	4.320	4.900
Net Profit/(Loss)	-0.250	1.222	2.011	2.710
Weighted Average Shares (fully diluted)	32.04	36.01	35.40	35.50
EPS adjusted (fully diluted) (pence)	10.8	10.8	11.5	12.4
Dividend	4.00	4.40	4.62	4.85
	£m	£m	£m	£m
Y/E March	FY 2015A	FY 2016A	FY 2017E	FY 2018E
CASH FLOW				
Net cash inflow/(outflow) from operating activities	3.336	3.718	4.741	5.660
Net cash inflow/(outflow) from investing activities	-10.039	-1.489	-6.938	-3.038
Net cash inflow/(outflow) from financing activities	7.242	-2.574	0.491	-2.850
Net increase/(decrease) in cash and cash equivalents in the year	0.539	-0.345	-1.706	-0.228
	£m	£m	£m	£m
Y/E March	FY 2015A	FY 2016A	FY 2017E	FY 2018E
BALANCE SHEET				
Assets				
Non-current assets	33.073	30.926	38.416	41.976
Current assets	19.582	22.216	20.278	20.828
Total Assets	52.655	53.142	58.694	62.804
Liabilities				
Current liabilities	-14.480	-17.770	-17.702	-15.802
Non-current liabilities	-11.826	-9.049	-11.823	-12.123
Total Liabilities	-26.306	-26.819	-29.525	-27.925
Net Assets	26.349	26.323	29.169	34.879
Net (debt)/cash	-11.400	-10.852	-16.090	-14.640

Source: Plastics Capital plc; Allenby Capital

DISCLAIMER

This document is issued by Allenby Capital Limited (Incorporated in England No.6706681), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority (“FCA”) for designated investment business, (Reg. No. 489795) and is a member of the London Stock Exchange.

This document is for information only and should not be regarded as an offer or solicitation to buy the securities or other instruments mentioned in it. It or any part of it do not form the basis of and should not be relied upon in connection with any contract.

Allenby Capital Limited uses reasonable efforts to obtain information from sources which it believes to be reliable but the contents of this document have been prepared without any substantive analysis being undertaken into the companies concerned or their securities and it has not been independently verified. No representation or warranty, either express or implied, is made nor responsibility of any kind is accepted by Allenby Capital Limited, its directors or employees either as to the accuracy or completeness of any information stated in this document. This document has not been prepared in accordance with legal requirements designed to promote the independence of investment research; and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Opinions expressed are our current opinions as of the date appearing on this material only. The information and opinions are provided for the benefit of Allenby Capital Limited clients as at the date of this document and are subject to change without notice. There is no regular update series for research issued by Allenby Capital Limited.

No personal recommendation is being made to you; the securities referred to may not be suitable for you and should not be relied upon in substitution for the exercise of independent judgement. Neither past performance nor forecasts are a reliable indication of future performance and investors may realise losses on any investments.

Allenby Capital Limited and any company or persons connected with it (including its officers, directors and employees) may have a position of holding in any investment mentioned in this document or a related investment and may from time to time dispose of any such securities or instrument. Allenby Capital Limited may have been a manager in the underwriting or placement of securities to the issuers of securities mentioned in this document within the last 12 months, or have received compensation for investment banking services from such companies within the last 12 months, or expect to receive or may intend to seek compensation for investment banking services from such companies within the next 3 months. Accordingly, recipients of this document should not rely on this document being impartial and information may be known to Allenby Capital Limited or persons connected with it which is not reflected in this material. Allenby Capital Limited has a policy in relation to the management of the firm’s conflicts of interest which is available upon request.

Allenby Capital Limited shall not be liable for any direct or indirect damages, including lost profits arising in any way from the information contained in this material. This material is for the use of intended recipients only and only for distribution to professional and institutional investors, i.e. persons having professional experience in investments who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 of the United Kingdom (such persons who do not have professional experience in matters relating to investments should not rely on this material), or persons who have been categorised by Allenby Capital Limited as Professional Clients or Eligible Counterparties. It is not intended for Retail Clients.

This document is being supplied to you solely for your information and may not be reproduced, re-distributed or passed to any other person or published in whole or in part for any purpose. The material in this document is not intended for distribution or use outside the European Economic Area except in the circumstances mentioned below to recipients in the United States. This material is not directed at you if Allenby Capital Limited is prohibited or restricted by any legislation or regulation in any jurisdiction from making it available to you and persons into whose possession this material comes should inform themselves about, and observe, any such restrictions.

Allenby Capital Limited may distribute research in reliance on Rule 15a-6(a)(2) of the Securities and Exchange Act 1934 to persons that are major US Institutional investors, however, transactions in any securities must be effected through a US registered broker-dealer. Any failure to comply with this restriction may constitute a violation of the relevant country’s laws for which Allenby Capital Limited does not accept responsibility.

By accepting this document, you agree that you have read the above disclaimer and to be bound by the foregoing limitations / restrictions.

RESEARCH RECOMMENDATION DISCLOSURE

Ian Jermin is the author of this research recommendation. Ian is employed by Allenby Capital Limited as an Equity Analyst.

Tel: 020-3328-5664

Email: i.jermin@allenbycapital.com

Unless otherwise stated the share prices used in this publication are taken at the close of business for the day prior to the date of publication.

* denotes that Allenby Capital acts as an Adviser to the Company

Information on research methodologies, definitions of research recommendations, and disclosure in relation to interests or conflicts of interests can be found at www.allenbycapital.com

Allenby Capital
3 St Helen’s Place London EC3A 6AB
+44 (0)20 3328 5656

www.allenbycapital.com